Pivotal Life Sciences — 2021 Investments
1 investments dated 2021 · listed companies and verified rows first · show all
DermBiont develops SM-030, a topical drug candidate targeting melasma, a skin pigmentation disorder, by inhibiting PKC-beta to address the underlying cause of hyperpigmentation.
BiotechDigital HealthMedical DevicesBoston, US
Robert Brucker(Executive Officer)inKarl R. Beutner(Executive Officer, Director)inNichola Eliovits(Executive Officer, Director)inMax Dawson(Executive Officer)in
BoardWilder Ramsey(Director)inJennifer Lee(Director)
Co-investorsCivilization Ventures Management, LlcJoyance PartnersOlive Tree CapitalStart CapitalToba CapitalValia Ventures+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.